Clinical trials: Choroidal Diseases
Choroidal Neovascularization, Macular Edema
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.
- Conditions
- Choroidal Neovascularization, Macular Edema, Glaucoma, Neovascular, Diabetic Retinopathy
- Trial name
- ECLIPSE (NCT01908816)
- Testing
- ranibizumab
- Where
- 39 sites in France
- Volunteers
- 270 people
- Sponsor
- Novartis Pharmaceuticals
Myopia, Refractive Error - Myopia
Minimum Power and Frequency of Repeated Low-level Red-light to Effectively Control Myopia Progression
To explore the minimum power and frequency of Repeated Low-level Red-light (RLRL) to control myopia progression in low-myopic children aged 8-10 years, and the rebound effect of low-myopic children after discontinuation of RLRL…
- Conditions
- Myopia, Refractive Error - Myopia, Choroidal Thickness, Retina
- Trial name
- NCT06717048
- Testing
- Repeated Low-level Red-light, Red LED
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Shanghai Eye Disease Prevention and Treatment Center
Myopic Choroidal Neovascularization
A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)
Being short sighted means that vision is blurry when looking at things far away. People with a condition called "pathologic myopia" are short sighted due to problems in the back layer of their eyes, also known as the retina.
- Trial name
- REALM (NCT04524910)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- Bayer
Age Related Macular Degeneration, Choroidal Neovascularization
Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)
To evaluate safety, visual acuity outcomes, persistence of choroidal neovascular leakage, and the number of treatments of combination intravitreal bevacizumab and verteporfin photodynamic therapy at standard or reduced fluence…
- Conditions
- Age Related Macular Degeneration, Choroidal Neovascularization, Macular Edema
- Trial name
- NCT00729846
- Testing
- Bevacizumab, verteporfin photodynamic therapy reduced fluence, verteporfin photodynamic therapy standardfluence
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- California Retina Consultants
Refractive Errors, Accommodation Disorder
Choroidal Thickness Change in Response to Physiological and Refractive Changes
There is a great need for precise and repeatable measurements of the choroidal thickness. Including the diurnal physiological changes, accommodation and refractive error impact on those measurements.
- Trial name
- NCT03906279
- Where
- Poland
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Wrocław University of Science and Technology
Age-related Macular Degeneration
Effects of Sildenafil on Choroidal Thickness in AMD
Choroidal thinning has been hypothesized to partake in the pathogenesis of age-related macular degeneration (AMD), but it is not known if increasing choroidal thickness may potentially alter the disease course.
- Trial name
- NCT01830790
- Testing
- Sildenafil citrate
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Duke University
Intracranial Hypertension
Invasive Versus Non Invasive Measurement of Intracranial Pressure in Brain Injury Trial (IMPRESSIT)
Investigators aim to assess sensitivity and specificity of transcranial doppler in ruling out intracranial hypertension in all patients admitted to intensive care unit for brain injury and needing Intracranial Pressure (ICP)…
- Trial name
- IMPRESSIT (NCT02322970)
- Testing
- transcranial Doppler
- Where
- Italy
- Volunteers
- 490 people
- Sponsor
- Università degli Studi di Brescia
Choroidal Neovascularization, Age-Related Macular Degeneration
Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)
Randomized controlled clinical trial of periocular corticosteroids as adjunctive therapy to photodynamic therapy (PDT) for patients with neovascular age-related macular degeneration (AMD).
- Trial name
- NCT00305630
- Testing
- Periocular injection of triamcinolone acetonide 40mg
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Johns Hopkins University
Choroidal Neovascularisation
Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen
This study is designed to provide efficacy and safety data in patients with choroidal neovascularisation (CNV) secondary to myopia using an individualized as-needed (PRN) dosing schedule.
- Trial name
- REPAIR (NCT01037348)
- Testing
- ranibizumab 0.5mg
- Where
- 12 sites in United Kingdom
- Volunteers
- 65 people
- Sponsor
- Novartis
Myopia, Pathological
VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)
VEGF Trap-Eye will be tested for safety and efficacy in patients with vision loss due to choroidal neovascularization secondary to pathologic myopia. This will be a placebo-controlled trial.
- Trial name
- Myrror (NCT01249664)
- Testing
- VEGF Trap-Eye (BAY86-5321), No Drug
- Where
- 20 sites in Hong Kong, Japan and 3 more
- Volunteers
- 122 people
- Sponsor
- Bayer
Elevated LDL Cholesterol
Oat and Cholesterol
The primary objective is to assess the effect of an oat ingredient provided over 4 weeks on serum LDL cholesterol in men and women with elevated LDL-cholesterol compared to a placebo.
- Trial name
- NCT03911427
- Testing
- Active oat beverage, Control rice beverage
- Where
- Canada
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Choroideremia
The Dark-Adapted Retinal Function Response in Choroideremia (DARC) Study
Choroideremia (CHM) is an inherited retinal disorder that causes progressive vision loss, ultimately leading to complete blindness.
- Trial name
- DARC (NCT05045703)
- Testing
- Vitamin A palmitate
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Duke University
Uveitis, Uveitis, Posterior
MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
This study is a non-interventional, observational extension of the Parent study, CLS1001-301 (NCT02595398). The purpose of this study is to characterize the continued clinical benefit(s) regarding safety and efficacy of…
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
- Trial name
- NCT02952001
- Testing
- 4 mg CLS-TA Suprachoriodal Injection
- Where
- 16 sites in United States, India
- Volunteers
- 33 people
- Sponsor
- Clearside Biomedical, Inc.
Macular Degeneration, Choroidal Neovascularization
Episcleral Brachytherapy for the Treatment of Wet AMD
This is a prospective, multi-site, safety and feasibility study of the SalutarisMD SMD-DA system for retrobulbar minimally invasive episcleral brachytherapy device in patients receiving and not responding to anti-VEGF therapy for…
- Trial name
- NEAMES (NCT02988895)
- Testing
- episcleral brachytherapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Salutaris Medical Devices, Inc.
Uveal Melanoma
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
- Trial name
- NCT07804186
- Testing
- Darovasertib, Crizotinib (Xalkori)
- Where
- 13 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- IDEAYA Biosciences
Angioid Streaks, Choroidal Neovascularization
Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks
Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks
- Trial name
- NCT00599820
- Testing
- Intravitreal Bevacizumab
- Where
- Mexico
- Sponsor
- Asociación para Evitar la Ceguera en México
Uveal Melanoma
Neoadjuvant Darovasertib in Primary Uveal Melanoma
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
- Trial name
- NCT07015190
- Testing
- Darovasertib, Primary Local Therapy
- Where
- 94 sites in United States, Australia and 19 more
- Volunteers
- 520 people
- Sponsor
- IDEAYA Biosciences
Choroidal Neovascularization
Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study
Efficacy of monthly intravitreal anti-vascular endothelial growth factor (VEGF) associated to systemic immunosuppression in patients with Vogt-Koyanagi-Harada Disease and choroidal neovascularization. Minimum follow-up 12 months.
- Trial name
- NCT02015351
- Testing
- bevacizumab
- Where
- Brazil
- Volunteers
- 9 people
- Sponsor
- University of Sao Paulo
Retinal Vein Occlusion
Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO
The study is intended to characterize the clinical benefit regarding safety and efficacy of a long term treatment with Lucentis in comparison with Ozurdex over an additional 6 months and a 3-month follow-up period, following the…
- Trial name
- NCT01580020
- Testing
- RFB002, Dexamethasone
- Where
- 37 sites in Germany
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Anterior Uveitis (AU), Birdshot Chorioretinitis
Quantification & Classification of Inflammatory Cells in Uveitis Using OCT
The goal of this study is to determine if it's possible to use a high resolution imaging device called optical coherence tomography (OCT) to develop an unbiased, standard method of counting and categorizing the various types of…
- Conditions
- Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus
- Trial name
- NCT07065747
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University